Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in Patients With Advanced Urothelial Carcinoma Treated With First‐Line Platinum‐Based Chemotherapy: A Multicenter Collaborative StudyFumihiko Urabe, Kojiro Tashiro, Yu Imai et al.|International Journal of Urology|2025Cited by 5
Effect of a variant histology on the oncological outcomes of Japanese patients with upper tract urothelial carcinomas after radical nephroureterectomy: a multicenter retrospective studyTakahiro Kimura, Keigo Sakanaka, Minoru Nakazono et al.|Translational Andrology and Urology|2024Cited by 5
Safety profile of enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial carcinoma: a multicenter Japanese cohort studyKosuke Iwatani, Takahiro Kimura, Fumihiko Urabe et al.|Japanese Journal of Clinical Oncology|2025Cited by 4
PSA Absolute Value Versus PSA Response Rate: Which Is More Valuable for Estimating Survival Outcomes With ARPI Treatment for Metastatic Hormone‐Sensitive Prostate Cancer (mHSPC) in Real‐World Analyses?Tatsuya Shimomura, Naoki Otsuka, Fumihiko Urabe et al.|The Prostate|2025Cited by 4
Clinical outcomes and treatment patterns of maintenance avelumab in locally advanced or metastatic urothelial carcinoma: a multicenter collaborative studyFumihiko Urabe, Naoki Uchida, Soshi Kadena et al.|Japanese Journal of Clinical Oncology|2025Cited by 2